ANGPTL3 deficiency and protection against coronary artery disease

Stitziel, Nathan O., Khera, Amit V., Wang, Xiao, Bierhals, Andrew J., Vourakis, A. Christina, Sperry, Alexandra E., Natarajan, Pradeep, Klarin, Derek +20 more·2017·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2017.02.030

Cited by (470)

Items 101–200 of 470

  1. Existing and emerging therapies for the treatment of familial hypercholesterolemia
    Robert S. Rosenson · 2021 · Journal of Lipid Research
  2. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
    Farzahna Mohamed, Brett Stephen Mansfield, Frederick Johan Raal · 2022 · Current Atherosclerosis Reports
  3. The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding
    Katrine Zinck Leth-Espensen, Kristian Kølby Kristensen, Anni Kumari, Anne-Marie Lund Winther, Stephen G. Young, Thomas J. D. Jørgensen, Michael Ploug · 2021 · Proceedings of the National Academy of Sciences
  4. Gene therapy and genome editing for lipoprotein disorders
    Chen Gurevitz, Archna Bajaj, Amit V. Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S. Rosenson · 2025 · European Heart Journal
  5. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases
    Xin Su, Daoquan Peng · 2018 · Lipids in Health and Disease
  6. Treatment of Dyslipidaemia in Children
    Riccardo Fiorentino, Francesco Chiarelli · 2021 · Biomedicines
  7. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Patrizia Tarugi, Stefano Bertolini, Sebastiano Calandra · 2018 · Journal of Biomedical Research
  8. The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
    Yi Wen, Yan Chen, Robert J. Konrad · 2022 · Advanced Biology
  9. Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
    Fabiana Hanna Rached, Marcio Hiroshi Miname, Viviane Zorzanelli Rocha, André Zimerman, Fernando Yue Cesena, Andrei Carvalho Sposito, Raul Dias Santos, Paulo Eduardo Ballvé Behr, Henrique Tria Bianco, Renato Jorge Alves et al. · 2025 · Arquivos Brasileiros de Cardiologia
  10. Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk
    Fredrik Landfors, Peter Henneman, Elin Chorell, Stefan K. Nilsson, Sander Kersten · 2024 · European Heart Journal Open
  11. Novel Therapeutic Targets for Managing Dyslipidemia
    Vasanth Sathiyakumar, Karan Kapoor, Steven Richard Jones, Maciej Banach, Seth Shay Martin, Peter Paul Toth · 2018 · Trends in Pharmacological Sciences
  12. DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes
    Connor A. Emdin, Amit V. Khera, Krishna G. Aragam, Mary E. Haas, Mark D. Chaffin, Derek M. Klarin, Pradeep Natarajan, Alexander G. Bick, Seyedeh Maryam Zekavat, Akihiro Nomura et al. · 2018 · Diabetes
  13. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
    Vesa M. Olkkonen, Juha P. Sinisalo, Matti Jauhiainen · 2018 · Atherosclerosis
  14. ANGPTL3 Inhibitors ― Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism ―
    Eleni V. Geladari, Panagiota Tsamadia, Natalia G. Vallianou · 2018 · Circulation Journal
  15. Mapping the sites of the lipoprotein lipase (LPL)–angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition
    Aspen Rene Gutgsell, Swapnil V. Ghodge, Albert A. Bowers, Saskia B. Neher · 2018 · Journal of Biological Chemistry
  16. ANGPTL3: a novel biomarker and promising therapeutic target
    Shuang Jiang, Guo-Hui Qiu, Neng Zhu, Zheyu Hu, Duan‐Fang Liao, Qin Li · 2019 · Journal of drug targeting
  17. Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
    Emmi Tikkanen, Ilenia Minicocci, Jenni Hällfors, Alessia Di Costanzo, Laura D’Erasmo, Eleonora Poggiogalle, Lorenzo M. Donini, Peter Würtz, Matti Jauhiainen, Vesa M. Olkkonen et al. · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
  18. Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency
    Marcello Arca, Laura D’Erasmo, Ilenia Minicocci · 2020 · Current Opinion in Lipidology
  19. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
    Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata · 2021 · Current Atherosclerosis Reports
  20. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Finney, Alexandra C., Das, Sandeep, Kumar, Dhananjay, McKinney, M. Peyton, Cai, Bishuang, Yurdagul, Arif, Rom, Oren · 2023 · Frontiers in Cardiovascular Medicine
  21. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
    Nick S. Nurmohamed, Geesje M. Dallinga‐Thie, Erik S.G. Stroes · 2020 · Expert Review of Cardiovascular Therapy
  22. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study
    Aliza Hussain, Caroline Sun, Elizabeth Selvin, Vijay Nambi, Josef Coresh, Xiaoming Jia, Christie Mitchell Ballantyne, Ron Cornelis Hoogeveen · 2021 · European Journal of Preventive Cardiology
  23. Genetics of hypertriglyceridemia and atherosclerosis
    Praneet K. Gill, Jacqueline S. Dron, Robert Alexander Hegele · 2021 · Current Opinion in Cardiology
  24. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins
    Sergio Fazio, Jessica Minnier, Michael David Shapiro, Sotirios Tsimikas, Patrizia Tarugi, Maurizio Rocco Averna, Marcello Arca, Hagai Tavori · 2017 · The Journal of Clinical Endocrinology & Metabolism
  25. Genome Editing
    Kiran Musunuru · 2017 · Journal of the American College of Cardiology
  26. Angiopoietin-Like Proteins: Cardiovascular Biology and Therapeutic Targeting for the Prevention of Cardiovascular Diseases
    Éric Thorin, Pauline Labbé, Mélanie Lambert, Pauline Mury, Olina Dagher, Géraldine Miquel, Nathalie Thorin‐Trescases · 2023 · Canadian Journal of Cardiology
  27. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Laurens F. Reeskamp, Tycho R. Tromp, Erik S.G. Stroes · 2020 · Current Opinion in Lipidology
  28. ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing
    Ellen M. Beauchamp, Matthew Joseph Leventhal, Elsa Bernard, Emma R. Hoppe, Gabriele Todisco, Maria Creignou, Anna Gallì, Cecilia A. Castellano, Marie E. McConkey, Akansha Tarun et al. · 2021 · Blood Cancer Discovery
  29. Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices
    Pradeep Natarajan, Akhil Pampana, Sarah E. Graham, Sanni Ruotsalainen, James A. Perry, Paul S. de Vries, Jai Broome, James P. Pirruccello, Michael C. Honigberg, Krishna G. Aragam et al. · 2021 · Nature Communications
  30. Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
    Waqas A. Malick, Ori Waksman, Ron Do, Wolfgang Köenig, Aruna D. Pradhan, Erik S.G. Stroes, Robert S. Rosenson · 2023 · Journal of the American College of Cardiology
  31. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk
    Émilie Gobeil, Jérôme Bourgault, Patricia L. Mitchell, Ursula Houessou, Éloi Gagnon, Arnaud S. Girard, Audrey Paulin, Hasanga D. Manikpurage, Valérie Côté, Christian Couture et al. · 2024 · European Heart Journal
  32. Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging
    Ibrahim A. Alradwan, Nojoud AL Fayez, Mohammad N. Alomary, Abdullah Awad Alshehri, Alhassan H. Aodah, Fahad A. Almughem, Khulud A. Alsulami, Ahmad M. Aldossary, Abdullah O. Alawad, Yahya M. K. Tawfik et al. · 2024 · Pharmaceutics
  33. Liraglutide protects cardiac function in diabetic rats through the PPARα pathway
    Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li, Miao Yu, Fan Ping, Tong Wang, Xiaojing Wang · 2018 · Bioscience Reports
  34. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
    Rai Ajit K. Srivastava · 2023 · Cells
  35. Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
    Mattía Galli, Antonio Abbate, Marc P. Bonaca, Filippo Crea, Maurizio Forte, Giacomo Frati, Mario F.L. Gaudino, Charles Michael Gibson, Diana A Gorog, Roxana Mehran et al. · 2026 · Nature Reviews Cardiology
  36. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
    Constantine E. Kosmas, Maria D. Bousvarou, Andreas Sourlas, Evangelia J. Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta, Eliscer Guzman · 2022 · Clinical Pharmacology Advances and Applications
  37. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
    Frederick Johan Raal, Robert S. Rosenson, Laurens F. Reeskamp, John J.P. Kastelein, Paolo Rubba, Paul Barton Duell, Masahiro Koseki, Erik S.G. Stroes, Shazia Ali, Poulabi Banerjee et al. · 2023 · JACC Advances
  38. Gene editing for dyslipidemias: New tools to “cut” lipids
    Sylvia G. Stankov, Marina Cuchel · 2023 · Atherosclerosis
  39. Integrated Control of Fatty Acid Metabolism in Heart Failure
    Xiaoting Li, Xukun Bi · 2023 · Metabolites
  40. ANGPTL3 Deficiency and Risk of Hepatic Steatosis
    Laura D’Erasmo, Michele Di Martino, Thomas Neufeld, Tyler J. Fraum, Chul Joo Kang, Kendall H. Burks, Alessia Di Costanzo, Ilenia Minicocci, Simone Bini, Marianna Maranghi et al. · 2023 · Circulation
  41. Understanding Hypertriglyceridemia: Integrating Genetic Insights
    Mara Alves, Francisco Laranjeira, Georgina Correia‐da‐Silva · 2024 · Genes
  42. Gene-based therapy in lipid management: the winding road from promise to practice
    Tycho R. Tromp, Erik S.G. Stroes, G. Kees Hovingh · 2020 · Expert Opinion on Investigational Drugs
  43. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
    Alexandra C. Chadwick, Kiran Musunuru · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
  44. Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape
    Francesca Fortini, Francesco Vieceli Dalla Sega, Luisa Marracino, Paolo Severi, Claudio Rapezzi, Paola Rizzo, Roberto Ferrari · 2021 · Biomedicines
  45. GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity
    Kristian Kølby Kristensen, Katrine Zinck Leth-Espensen, Anni Kumari, Anne Louise Grønnemose, Anne-Marie Lund Winther, Stephen G. Young, Michael Ploug · 2021 · Frontiers in Cell and Developmental Biology
  46. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia
    Sophie Béliard, Samir Saheb, Stéphanie Litzler-Renault, Alexandre Vimont, René Valéro, Éric Bruckert, Michel Farnier, Antonio Gallo · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
  47. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Kiran Musunuru · 2020 · Annual Review of Medicine
  48. Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease
    Le Shu, Montgomery Blencowe, Xia Yang · 2018 · Frontiers in Cardiovascular Medicine
  49. Lipid-Modifying Therapies and Stroke Prevention
    Daniel G. Hackam, Robert Alexander Hegele · 2022 · Current Neurology and Neuroscience Reports
  50. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
    Umidakhon Makhmudova, Elisabeth Steinhagen‐Thiessen, Massimo Volpe, Ulf Landmesser · 2024 · Cardiovascular Research
  51. Can targeting ANGPTL proteins improve glucose tolerance?
    Brandon S.J. Davies · 2018 · Diabetologia
  52. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
    Jacqueline S. Dron, Aniruddh P. Patel, Yiyi Zhang, Sean Joseph Jurgens, Dimitri J. Maamari, Minxian Wang, Eric Boerwinkle, Alanna C. Morrison, Paul S. de Vries, Myriam Fornage et al. · 2023 · JAMA Cardiology
  53. State of the Art and Perspectives of Gene Therapy in Heart Failure. A Scientific Statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases
    Sophie Van Linthout, Konstantinos Stellos, Mauro Giacca, Edoardo Bertero, Antonio Nicola Cannata, Lucie Carrier, Pablo García‐Pavía, Alessandra Ghigo, Arantxa González, Kristina Hermann Haugaa et al. · 2024 · European Journal of Heart Failure
  54. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia
    Farzahna Mohamed, Theunis C. Botha, Frederick Johan Raal · 2021 · Current Opinion in Lipidology
  55. Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
    Ana Clara Aprotosoaie, Alexandru Dan Costache, Irina Iuliana Costache · 2022 · Pharmaceutics
  56. Associations between circulating full-length angiopoietin-like protein 8 levels and severity of coronary artery disease in Chinese non-diabetic patients: a case–control study
    Xiaolu Jiao, Jiqiang He, Yunyun Yang, Song Yang, Juan Li, Yanwen Qin · 2018 · Cardiovascular Diabetology
  57. A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
    Alexandra Fowler, Maureen L. Sampson, Alan Thomas Remaley, Bryce Chackerian · 2021 · Vaccine
  58. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
    Archna Bajaj, Marina Cuchel · 2022 · Journal of Atherosclerosis and Thrombosis
  59. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
    William R. Lang, William H. Frishman · 2019 · Cardiology in Review
  60. Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
    Kausik Kumar Ray, Helle Linnebjerg, Laura F. Michael, Xi Ping Shen, Xiaosu Ma, Shufen Lim, Yuejun Zhen, Henryk Dudek, Marc Abrams, Utsav H. Saxena et al. · 2025 · Journal of the American College of Cardiology
  61. Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology
    Hayato Tada, Soichiro Usui, Kenji Sakata, Masayuki Takamura, Masa‐aki Kawashiri · 2020 · Journal of Atherosclerosis and Thrombosis
  62. Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the “Prime Time” of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?
    H. J. Yang, Li Xiao, Danyan Xu · 2020 · Cardiovascular Drugs and Therapy
  63. Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE−/− mice
    Xiaolu Jiao, Yunyun Yang, Linyi Li, Huahui Yu, Yunxiao Yang, Juan Li, Yunhui Du, Jing Zhang, Chaowei Hu, Yanwen Qin · 2020 · Atherosclerosis
  64. New insights into the pathological development of dyslipidemia in patients with hypothyroidism
    Xin Su, Xiang Chen, Hua Peng, Jingjin Song, Bin Wang, Xijie Wu · 2021 · Bosnian Journal of Basic Medical Sciences
  65. Emerging Anti-Atherosclerotic Therapies
    Anna Gluba-Brzózka, Beata Franczyk, Magdalena Rysz-Górzyńska, Janusz Ławiński, Jacek Rysz · 2021 · International Journal of Molecular Sciences
  66. Emerging Targets for Cardiovascular Disease Prevention in Diabetes
    Nathan O. Stitziel, Jenny E. Kanter, Karin Bornfeldt · 2020 · Trends in Molecular Medicine
  67. GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice
    Xuedan Li, Yiliang Zhang, Minzhu Zhang, Yan Wang · 2020 · Scientific Reports
  68. Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
    Paolo Raggi, Maria Laura Becciu, Eliano Pio Navarese · 2024 · Current Opinion in Lipidology
  69. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
    Frederick Johan Raal, Jean Bergeron, Daniel Gaudet, Robert S. Rosenson, DAVID R. SULLIVAN, Traci A. Turner, Robert Alexander Hegele, Christie Mitchell Ballantyne, Joshua W. Knowles, Nicholas James Leeper et al. · 2025 · The Lancet Diabetes & Endocrinology
  70. Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization
    Michael G. Levin, Rachel L. Kember, Renae Judy, David L. Birtwell, Heather Williams, Zoltan Pierre Arany, Jay S. Giri, Marie A. Guerraty, Tom Cappola, Jinbo Chen et al. · 2018 · Circulation Genomic and Precision Medicine
  71. Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
    Ting Sun, Wanlin Zhan, Lijiang Wei, Zuojun Xu, Fan Li, Zhuo Yang, Changqian Wang, Junfeng Zhang · 2021 · Lipids in Health and Disease
  72. Drug development advances in human genetics‐based targets
    Xiaoxia Zhang, Wenjun Yu, Yan Li, Aiping Wang, Haiqiang Cao, Yuanlei Fu · 2024 · MedComm
  73. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
    Marcio Hiroshi Miname, Viviane Zorzanelli Rocha, Raul Dias Santos · 2021 · Current Atherosclerosis Reports
  74. In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease
    Jennifer Khirallah, Hanan Bloomer, Douglas Wich, Changfeng Huang, J. Noah Workman, Yamin Li, Gregory A. Newby, David R. Liu, Qiaobing Xu · 2025 · Molecular Therapy — Nucleic Acids
  75. DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke
    Weijun Li, Rui‐Xing Yin, Xiaoli Cao, Wu‐Xian Chen, Feng Huang, Jin‐Zhen Wu · 2018 · Lipids in Health and Disease
  76. Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
    Kyriakos E. Kypreos, Rafael Bitzur, Eleni A. Karavia, Eva Xepapadaki, George D. Panayiotakopoulos, Caterina Constantinou · 2018 · Angiology
  77. Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase
    Anni Kumari, Anne Louise Grønnemose, Kristian Kølby Kristensen, Anne-Marie Lund Winther, Stephen G. Young, Thomas J. D. Jørgensen, Michael Ploug · 2023 · Proceedings of the National Academy of Sciences
  78. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study
    Massimiliano Ruscica, Chiara Macchi, Federica Fogacci, Nicola Ferri, Elisa Grandi, Elisabetta Rizzoli, Sergio D’Addato, Claudio Borghi, Arrigo F.G. Cicero · 2019 · European Journal of Preventive Cardiology
  79. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
    Ji Yoon Kim, Nam Hoon Kim · 2023 · Journal of Lipid and Atherosclerosis
  80. Is ANGPTL3 the next PCSK9?
    Kiran Musunuru, Sekar Kathiresan · 2017 · Nature Reviews Endocrinology
  81. ANGPTL3 possibly promotes cardiac angiogenesis through improving proangiogenic ability of endothelial progenitor cells after myocardial infarction
    Fei Luo, Panyun Wu, Jingfei Chen, Yuan Guo, Jiangang Wang, Xiangping Li, Zhenfei Fang · 2018 · Lipids in Health and Disease
  82. Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
    Kendall H. Burks, Nathan O. Stitziel, Nicholas O. Davidson · 2024 · Cellular and Molecular Gastroenterology and Hepatology
  83. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
    Christie Mitchell Ballantyne, Giuseppe Danilo Norata · 2025 · European Heart Journal
  84. Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes
    Marina Harada, Tadashi Yamakawa, Rie Kashiwagi, Akeo Ohira, Mai Sugiyama, Yasuyuki Sugiura, Yoshinobu Kondo, Yasuo Terauchi · 2021 · PLoS ONE
  85. Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia
    Hayato Tada, Masa‐aki Kawashiri, Atsushi Nohara, Tomoko Sekiya, Atsushi Watanabe, Masayuki Takamura · 2024 · Genes
  86. Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss
    Rufeng Dai, Haimei Liu, Xinli Han, Junchao Liu, Yi­hui Zhai, Jia Rao, Qian Shen, Hong Ming Xu · 2019 · BMC Nephrology
  87. Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
    Xinjie Lu · 2019 · Current Medicinal Chemistry
  88. New and Emerging lipid-lowering Therapy
    James M. Backes, Daniel E. Hilleman · 2021 · Future Cardiology
  89. Angiopoietin-like 3: An important protein in regulating lipoprotein levels
    Kendall H. Burks, Debapriya Basu, Ira J. Goldberg, Nathan O. Stitziel · 2022 · Best Practice & Research Clinical Endocrinology & Metabolism
  90. Updates in Small Interfering RNA for the Treatment of Dyslipidemias
    Stefano Carugo, Cesare Riccardo Sirtori, Guido Gelpi, Alberto Corsini, Lale S Tokgözoğlu, Massimiliano Ruscica · 2023 · Current Atherosclerosis Reports
  91. Cholesterol-Lowering Drugs
    E.L. Albuquerque, Umberto Laino Fulco, E. W. S. Caetano, V. N. Freire · 2020 · Cambridge University Press eBooks
  92. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases
    Benoît J. Arsenault, Nicolas Perrot, Rishi Puri · 2018 · Clinical Pharmacology & Therapeutics
  93. Triglycerides and cardiovascular risk: Apolipoprotein B holds the key
    Jane K. Stock · 2019 · Atherosclerosis
  94. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well
    Xiaoming Jia, Mahmoud Al Rifai, Aliza Hussain, Seth Shay Martin, Anandita Agarwala, Salim S. Virani · 2020 · Current Atherosclerosis Reports
  95. Functional Assays to Screen and Dissect Genomic Hits
    Kiran Musunuru, Daniel Bernstein, Francis Sessions Cole, Mustafa Kezar Khokha, Frank S. Lee, Shin Lin, Thomas V. McDonald, Ivan P. G. Moskowitz, Thomas Quertermous, Vijay G. Sankaran et al. · 2018 · Circulation Genomic and Precision Medicine
  96. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
    Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2024 · International Journal of Molecular Sciences
  97. A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia
    Malihe Aghasizadeh, Reza Zare‐Feyzabadi, Toba Kazemi, Amir Avan, Gordon A. Ferns, Habibollah Esmaily, Ebrahim Miri‐Moghaddam, Majid Ghayour‐Mobarhan · 2021 · Gene
  98. Low cholesterol states: clinical implications and management
    Praneet K. Gill, Robert Alexander Hegele · 2023 · Expert Review of Endocrinology & Metabolism
  99. Recent advances in the management and implementation of care for familial hypercholesterolaemia
    Nick S.R. Lan, Archna Bajaj, Gerald Francis Watts, Marina Cuchel · 2023 · Pharmacological Research
  100. Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes
    Madelynn N. Whittaker, Lauren C. Testa, Aidan Quigley, Ishaan Jindal, Saúl V. Cortez-Alvarado, Ping Qü, Yifan Yang, Mohamad‐Gabriel Alameh, Kiran Musunuru, Xiao Wang · 2023 · Arteriosclerosis Thrombosis and Vascular Biology